HCPLive Network

Even Correctly Administered NSAIDs Can Cause Acute Kidney Injury in Kids

 
TUESDAY, Jan. 29 (HealthDay News) -- Nonsteroidal anti-inflammatory drug (NSAID)-associated acute kidney injury (AKI) accounts for almost 3 percent of pediatric AKI, according to a study published online Jan. 28 in The Journal of Pediatrics.

Jason M. Misurac, M.D., from Indiana University in Indianapolis, and colleagues retrospectively reviewed the charts of 1,015 children with a diagnosis of AKI to characterize NSAID-linked AKI. A diagnosis explaining AKI or comorbid clinical conditions predisposing to AKI development negated a classification of NSAID-associated AKI.

The researchers found that 21 children had clinical, laboratory, and radiographic studies suggesting NSAID-associated acute tubular necrosis and six had findings suggesting NSAID-associated acute interstitial nephritis, representing 2.7 percent of the total cohort with AKI. The median age for children with NSAID-associated AKI was 14.7 years and four patients were younger than 5 years. Of the 20 children for whom dosing data were available, 75 percent received NSAIDs within recommended dosing limits. Dialysis, intensive care unit admission, and longer length of stays were significantly more likely in children younger than 5 years of age.

"NSAID-associated AKI accounted for 2.7 percent of AKI in this pediatric population," the authors write. "AKI typically occurred after the administration of correctly dosed NSAIDs. Young children with NSAID-associated AKI may have increased disease severity."
 

Abstract
Full Text (subscription or payment may be required)


Copyright © 2013 HealthDay. All rights reserved.
 
 
 

Further Reading
Atherosclerotic internal carotid artery disease is a major contributor to ischemic stroke. Surgeons use a combination of carotid artery and brain imaging to determine if patients have symptomatic carotid stenosis. However, there remains widespread disagreement on the threshold, timing, and best technical approach to carotid revascularization in symptomatic patients.
The FDA has cleared a blood test that can screen patients, especially black women, for coronary heart disease.
The US Food and Drug Administration has announced the approval of a new combination treatment for hepatitis C virus.
More Reading